Johnson & Johnson
JNJHealthcareNASDAQDrug Manufacturers - General · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Johnson & Johnson focuses on Drug Manufacturers - General services and products. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. Valued at $542.42B, JNJ is a mega-cap name in its sector. It operates in two segments, Innovative Medicine and MedTech.
Market Cap
$542.42B
Beta
0.26
P/E (TTM)
26.11
P/E (Fwd)
17.72
EPS (TTM)
$8.63
EPS (Fwd)
$12.72
ROE
26.4%
ROA
8.4%
Cash
$22.05B
Total Debt
$54.99B
Free CF
$12.51B
52W Change
45.0%
Annual Financials
Cash vs Debt
The company holds $22.05B in cash, though total debt stands at $54.99B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $12.51B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 26.4%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $79.99B to $94.19B.
The relatively low beta of 0.26 suggests JNJ is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing JNJ's risk profile alongside its fundamentals and technical indicators provides a more complete picture.